Acticor Biotech Reports on Liquidity Contract with Kepler Cheuvreux
2 Sources
2 Sources
[1]
Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2024: The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice. About ACTICOR BIOTECH Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke. The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the Lancet Neurology (link to publication) confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. A post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence confirmed these results, showing a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab. On April 25, 2024, the company announced the initial results of the international phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke, which showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2). On May 15, 2024, Prof. Martin Köhrmann (Principal Investigator of ACTISAVE) presented the main results of the study at the opening session of the European Stroke Organization Conference (ESOC), confirming the neutrality of the study on the primary and secondary endpoints, and showing trends in return to normal life (mRS 0-1), notably in sub-populations of patients with complete recanalization after mechanical thrombectomy. Glenzocimab is being evaluated in 2 other clinical trials initiated by academic teams: Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT).
[2]
Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux By Investing.com
ACTICOR BIOTECH (ISIN: FR0014005OJ5 " ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024: The implementation of this report is carried out in accordance with AMF Decision N °2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice. About ACTICOR BIOTECH Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke. The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the Lancet Neurology (link to publication) confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. A post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence confirmed these results, showing a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab. On April 25, 2024, the company announced the initial results of the international phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke, which showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2). On May 15, 2024, Prof. Martin Köhrmann (Principal Investigator of ACTISAVE) presented the main results of the study at the opening session of the European Stroke Organization Conference (ESOC), confirming the neutrality of the study on the primary and secondary endpoints, and showing trends in return to normal life (mRS 0-1), notably in sub-populations of patients with complete recanalization after mechanical thrombectomy. Glenzocimab is being evaluated in 2 other clinical trials initiated by academic teams: Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT). For more information, visit: www.acticor-biotech.com
Share
Share
Copy Link
Acticor Biotech releases its half-year report on the liquidity contract with brokerage firm Kepler Cheuvreux, showing an increase in available resources and share transactions.
Background
Acticor Biotech, a clinical-stage biotechnology company focused on developing innovative treatments for cardiovascular emergencies, has released its half-year report on the liquidity contract with brokerage firm Kepler Cheuvreux. The report covers the period from January 1, 2023, to June 30, 2023, providing insights into the company's share performance and liquidity management
1
2
.Key Figures
As of June 30, 2023, the following resources were available in the liquidity account:
- 30,717 shares of Acticor Biotech
- €51,703.20 in cash
These figures represent a significant change from the previous reporting period, which ended on December 31, 2022. At that time, the liquidity account contained:
- 13,400 shares of Acticor Biotech
- €135,386.13 in cash
1
2
Transaction Volume
During the first half of 2023, the following transactions were executed under the liquidity contract:
- Buy side: 52,414 shares purchased, totaling €240,280.69 (702 transactions)
- Sell side: 35,097 shares sold, totaling €156,597.76 (431 transactions)
1
2
These figures demonstrate active management of the company's shares in the market, aimed at maintaining liquidity and stability in the stock price.
Regulatory Compliance
The liquidity contract with Kepler Cheuvreux operates in accordance with the legal framework in force, specifically the AMF Decision n°2021-01 dated June 22, 2021. This regulatory compliance ensures transparency and fairness in the execution of the liquidity contract
1
2
.Related Stories
Company Profile
Acticor Biotech (ISIN: FR0014005OJ5, ALACT) is a clinical-stage biotechnology company established in 2013. The company focuses on developing innovative treatments for cardiovascular emergencies, including ischemic stroke. Acticor Biotech is listed on the Euronext Growth Paris market, highlighting its position as a publicly traded entity in the biotech sector
1
2
.Implications
The increase in the number of Acticor Biotech shares held in the liquidity account, from 13,400 to 30,717, suggests a strategic move to enhance market liquidity. However, the decrease in cash balance from €135,386.13 to €51,703.20 indicates that a significant portion of the cash was utilized to acquire additional shares. This reallocation of resources within the liquidity contract demonstrates the company's commitment to maintaining an active presence in the market and potentially stabilizing its stock price.
References
Summarized by
Navi
[1]
Related Stories
Weekly Highlights
Weekly Highlights
Today's Top Stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
